HUTCHMED-small-spaced-1000x305-WhiteBgd.png
HUTCHMED Highlights Publication of Phase III ESLIM-01 Results in The Lancet Haematology
June 16, 2024 20:00 ET | HUTCHMED (China) Limited
— Publication shows treatment demonstrated durable response rate of 48.4% vs. 0% with placebo — — Presentations at EHA showcased subgroup analyses demonstrating consistent benefits regardless of...
HUTCHMED-small-spaced-1000x305-WhiteBgd.png
HUTCHMED Initiates Phase I Trial of Menin Inhibitor HMPL-506 in Patients with Hematological Malignancies in China
June 06, 2024 20:00 ET | HUTCHMED (China) Limited
HONG KONG and SHANGHAI and FLORHAM PARK, N.J., June 06, 2024 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:HCM; HKEX:13) today announces that it has initiated Phase I...
HUTCHMED-small-spaced-1000x305-WhiteBgd.png
HUTCHMED Highlights Publication of Phase III FRUTIGA Results in Nature Medicine
June 02, 2024 20:00 ET | HUTCHMED (China) Limited
HONG KONG and SHANGHAI and FLORHAM PARK, N.J., June 03, 2024 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:​HCM; HKEX:​13) today announces that results from FRUTIGA,...
HUTCHMED-small-spaced-1000x305-WhiteBgd.png
HUTCHMED Highlights Presentations at the 2024 ASCO Annual Meeting
May 23, 2024 20:00 ET | HUTCHMED (China) Limited
HONG KONG and SHANGHAI, China and FLORHAM PARK, N.J., May 23, 2024 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:HCM; HKEX:13) today announces that new and updated data from...
HUTCHMED-small-spaced-1000x305-WhiteBgd.png
HUTCHMED announces retirement of Chairman, appointment of new Chairman and change of members of board committees
May 17, 2024 10:00 ET | HUTCHMED (China) Limited
HONG KONG and SHANGHAI and FLORHAM PARK, N.J., May 17, 2024 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED” or the “Company”) (Nasdaq/AIM:​HCM, HKEX:​13) today announces:- (a) the...
HUTCHMED-small-spaced-1000x305-WhiteBgd.png
HUTCHMED Highlights Sovleplenib Phase III ESLIM-01 Study and Hematological Malignancy Programs Data to be Presented at the upcoming EHA2024 Congress
May 16, 2024 20:00 ET | HUTCHMED (China) Limited
HONG KONG, SHANGHAI and FLORHAM PARK, N.J., May 17, 2024 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:HCM; HKEX:13) today announces that topline and subgroup results from...
HUTCHMED-small-spaced-1000x305-WhiteBgd.png
HUTCHMED Initiates the RAPHAEL Registrational Phase III Trial of HMPL-306 for Patients with IDH1- and/or IDH2-Mutated Relapsed/Refractory Acute Myeloid Leukemia in China
May 13, 2024 20:00 ET | HUTCHMED (China) Limited
HONG KONG and SHANGHAI, China and FLORHAM PARK, N.J., May 14, 2024 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:HCM; HKEX:13) today announces that it has initiated a...
HUTCHMED-small-spaced-1000x305-WhiteBgd.png
HUTCHMED Initiates Phase II/III Trial of the Combination of Surufatinib and Camrelizumab for Treatment-Naïve Pancreatic Ductal Adenocarcinoma in Collaboration with Hengrui
May 13, 2024 20:00 ET | HUTCHMED (China) Limited
— Almost half a million people diagnosed each year across the globe — — Collaboration based on synergistic potential of inhibiting angiogenesis and tumor-associated macrophages with HUTCHMED’s...
HUTCHMED-small-spaced-1000x305-WhiteBgd.png
HUTCHMED Announces Appointment of Independent Non-executive Director and Member of Board Committee
May 08, 2024 04:30 ET | HUTCHMED (China) Limited
HONG KONG, SHANGHAI, China and FLORHAM PARK, N.J., May 08, 2024 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED” or the “Company”) (Nasdaq/AIM: ​HCM, HKEX:​ 13) today announces that Dr Renu...
HUTCHMED-small-spaced-1000x305-WhiteBgd.png
HUTCHMED Announces Positive CHMP Opinion for Fruquintinib in Previously Treated Metastatic Colorectal Cancer Received by Takeda
April 26, 2024 08:30 ET | HUTCHMED (China) Limited
— If approved in the European Union, fruquintinib will be the first novel targeted therapy for metastatic colorectal cancer regardless of biomarker status in over a decade — — Positive opinion based...